BioVie prices $4.74 million offering, closes November 5

BioVie sold shares and pre-funded warrants in a registered direct offering alongside a private placement of common warrants, with proceeds earmarked for working capital.

BioVie Inc. (NASDAQ: BIVI) priced a registered direct offering and concurrent private placement on November 3, 2026, raising gross proceeds of approximately $4.74 million. The offering closed on November 5, 2026, according to the company's Form 8-K. The Offering closed on November 5, 2026.¹

Under the purchase agreement, BioVie agreed to issue and sell 960,000 shares of Class A common stock at $1.60 per share, along with 2,002,500 pre-funded warrants priced at $1.5999 per warrant in lieu of additional shares, with each pre-funded warrant carrying a $0.0001 exercise price.¹ In a concurrent private placement, the Company also agreed to issue 2,962,500 common warrants to purchase up to 2,962,500 shares of common stock.¹

A.G.P./Alliance Global Partners acted as exclusive placement agent and will receive a cash fee equal to 7.0% of gross proceeds plus reimbursed expenses.¹ BioVie agreed not to issue additional securities or enter variable rate transactions for specified periods following closing, subject to exceptions.¹ Company directors and executive officers also signed lock-up agreements restricting sales of their holdings for 60 days after closing.¹

Fact check notes

Checker's noteThe entry asserts the press release and 8-K describe the common warrants' exercisability/expiration terms 'somewhat differently,' but the two descriptions are mathematically equivalent (6-month delay to exercise, expiring 5 years after that = 5.5 years from issuance), so there is no actual discrepancy to report.
Sentence removedThe aggregate gross proceeds to the Company from the Offering were approximately $4.74 million, before deducting placement agent fees and other offering expenses.copied source wording
Sentence removedThe two filings describe the common warrants' term somewhat differently.contradicted: Both descriptions are mathematically identical (6 months to exercise + 5 years thereafter = 5.5 years from issuance). The entry incorrectly characterizes consistent terms as differing.
Sentence removedThe pricing press release states the common warrants will have an exercise price of $1.70 per share, will be exercisable six months following their issuance and will expire five and a half years from the issuance date.copied source wording
Sentence removedThe 8-K itself specifies that each Common Warrant has an exercise price of $1.70 per share, will be exercisable beginning on the six-month anniversary of the date of issuance and will expire on the five-year anniversary of that Initial Exercise Date.copied source wording
Sentence removedBioVie intends to use the net proceeds from the offering for working capital and general corporate purposes.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.